EGFR and non-small cell lung carcinoma: In non-small cell lung cancer (NSCLC), the Cet resistance is due to the dysregulation of oncogenic shift, explaining that the resistant NSCLC rely on the activation of various receptor tyrosine kinases and their subsequent hetero-dimerization with EGFR to bypass Cet blockage [22,27].